Galia Rahav

11.6k total citations · 2 hit papers
194 papers, 5.4k citations indexed

About

Galia Rahav is a scholar working on Infectious Diseases, Epidemiology and Food Science. According to data from OpenAlex, Galia Rahav has authored 194 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Infectious Diseases, 74 papers in Epidemiology and 25 papers in Food Science. Recurrent topics in Galia Rahav's work include SARS-CoV-2 and COVID-19 Research (32 papers), Salmonella and Campylobacter epidemiology (22 papers) and Antimicrobial Resistance in Staphylococcus (20 papers). Galia Rahav is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (32 papers), Salmonella and Campylobacter epidemiology (22 papers) and Antimicrobial Resistance in Staphylococcus (20 papers). Galia Rahav collaborates with scholars based in Israel, United States and Germany. Galia Rahav's co-authors include Ohad Gal‐Mor, Itzchak Levy, Gili Regev‐Yochay, ‪Yasmin Maor‬‏, Nathan Keller, Gili Aviv, Yaniv Lustig, Michael McClelland, Prerak Desai and Victoria Indenbaum and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Galia Rahav

190 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

2021 199 citations Tal Brosh‐Nissimov, Efrat Orenbuch‐Harroch et al. Clinical Microbiology and Infection profile →
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

2021 161 citations Johan Maertens, Galia Rahav et al. profile →

Peers

Countries citing papers authored by Galia Rahav

Since Specialization

Citations

This map shows the geographic impact of Galia Rahav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galia Rahav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galia Rahav more than expected).

Fields of papers citing papers by Galia Rahav

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galia Rahav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galia Rahav. The network helps show where Galia Rahav may publish in the future.

Co-authorship network of co-authors of Galia Rahav

This figure shows the co-authorship network connecting the top 25 collaborators of Galia Rahav. A scholar is included among the top collaborators of Galia Rahav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galia Rahav. Galia Rahav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS) 2025 ·Clinical Infectious Diseases ·Michael R. Hodges, Margaret Tawadrous, Oliver A. Cornely, George R. Thompson, Monica A. Slavin, Johan Maertens, Sanjeet Dadwal, Galia Rahav, Susan Hazel, Mary Almas, Abhijeet Jakate, Rienk Pypstra	9
2	A new Salmonella enterica serovar that was isolated from a wild sparrow presents a distinct genetic, metabolic and virulence profile 2023 ·Microbes and Infection ·Emiliano Cohen, (unknown), Oren Auster, Adiv Gal, (unknown), Sam Crauwels, Galia Rahav, Ohad Gal‐Mor	2
3	Group B streptococcus virulence factors associated with different clinical syndromes: Asymptomatic carriage in pregnant women and early-onset disease in the newborn 2023 ·Frontiers in Microbiology ·(unknown), Galia Rahav, Israel Nissan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), ‪Yasmin Maor‬‏	9
4	Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders 2023 ·PLoS ONE ·Hila Magen, Abraham Avigdor, (unknown), Shalev Fried, (unknown), E G Levin, Yaniv Lustig, (unknown), Galia Rahav	1
5	Complicated Pocket Infection in Patients Undergoing Lead Extraction: Characteristics and Outcomes 2023 ·Journal of Clinical Medicine ·Anat Milman, Anat Wieder-Finesod, (unknown), (unknown), (unknown), (unknown), Roy Beinart, Galia Rahav, Eyal Nof	1
6	Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose 2022 ·Clinical Infectious Diseases ·Tal Brosh‐Nissimov, Khetam Hussein, Yonit Wiener‐Well, Efrat Orenbuch‐Harroch, Meital Elbaz, (unknown), ‪Yasmin Maor‬‏, (unknown), Bibiana Chazan, (unknown), Galia Rahav, Oren Zimhony, (unknown), Michal Chowers	25
7	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant 2022 ·The Journal of Heart and Lung Transplantation ·Yael Peled, Arnon Afek, Yitshak Kreiss, Galia Rahav, Ital Nemet, Limor Kliker, Victoria Indenbaum, Eilon Ram, Jacob Lavee, Amit Segev, (unknown), Leonid Sternik, Ehud Raanani, Yaniv Lustig, J. Patel, Michal Mandelboim	9
8	First report of myocarditis in two patients with COVID-19 Omicron variant: case report 2022 ·European Heart Journal - Case Reports ·Boris Fishman, Orly Goitein, Anat Berkovitch, Galia Rahav, Shlomi Matetzky	9
9	Myocardial injury in hospitalized patients with COVID-19 infection—Risk factors and outcomes 2021 ·PLoS ONE ·(unknown), Noam Barda, (unknown), Avshalom Leibowitz, Alexander Fardman, Galia Rahav, Robert Klempfner, Ehud Grossman	18
10	Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience 2021 ·The Journal of Heart and Lung Transplantation ·Yael Peled, Eilon Ram, Jacob Lavee, Amit Segev, (unknown), Anat Wieder-Finesod, Rebecca F. Halperin, Michal Mandelboim, Victoria Indenbaum, Itzchak Levy, Leonid Sternik, Ehud Raanani, Arnon Afek, Yitshak Kreiss, Yaniv Lustig, Galia Rahav	78
11	Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen) 2021 ·BMJ Open ·Roni Bitterman, Fidi Koppel, Cristina Mussini, Yuval Geffen, Michal Chowers, Galia Rahav, Lior Nesher, Ronen Ben‐Ami, ‪Adi Turjeman‬‏, (unknown), Matthew P. Cheng, Todd C. Lee, Leonard Leibovici, Dafna Yahav, Mical Paul	17
12	Rituximab identified as an independent risk factor for severe PJP: A case-control study 2020 ·PLoS ONE ·(unknown), Ronen Ben‐Ami, Galia Rahav, Danny Alon, Allon E. Moses, (unknown), Miriam Weinberger, Pnina Shitrit, Michal Katzir, (unknown), Michal Chowers	18
13	Underperformed and Underreported Testing for Persistent Oropharyngeal Poliovirus Infections in Primary Immune Deficient Patients—Risk for Reemergence of Polioviruses 2020 ·Journal of the Pediatric Infectious Diseases Society ·Lester M. Shulman, Merav Weil, Raz Somech, Tali Stauber, Victoria Indenbaum, Galia Rahav, Ella Mendelson, Danit Sofer	0
14	Patterns and Predictors of Staphylococcus aureus Carriage during the First Year of Life: a Longitudinal Study 2019 ·Journal of Clinical Microbiology ·(unknown), Carmit Rubin, (unknown), Ilya Novikov, Hanaa Jaber, (unknown), Laurence S. Freedman, Galia Rahav, Gili Regev‐Yochay	8
15	Missed opportunities for earlier diagnosis of HIV in patients who presented with advanced HIV disease: a retrospective cohort study 2016 ·BMJ Open ·Itzchak Levy, ‪Yasmin Maor‬‏, Naim Mahroum, Liraz Olmer, (unknown), (unknown), Orna Mor, Galia Rahav	41
16	Phase 3 Randomized, Double-Blind Trial Evaluating Isavuconazole vs. Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Spp. or Other Filamentous Fungi (SECURE) 2015 ·Mycoses ·Johan Maertens, Thomas F. Patterson, Galia Rahav, D. P. Kontoyiannis, Kieren A. Marr, (unknown), (unknown), Bernhardt Zeiher, Andrew J. Ullmann	4
17	Primary Versus Nonprimary West Nile Virus Infection: A Cohort Study 2015 ·The Journal of Infectious Diseases ·Galia Rahav, (unknown), ‪Yasmin Maor‬‏, Gilad Yahalom, Musa Hindiyeh, Ella Mendelson, Hanna Bin	1
18	Opportunity for Healthy Ageing: Lessening the Burden of Adult Pneumococcal Disease in Central and Eastern Europe, and Israel 2012 ·Central European Journal of Public Health ·Endre Ludwig, Serhat Ünal, Miron Alexandru Bogdan, Roman Chlíbek, Yavor Ivanov, Roman S. Kozlov, Mark van der Linden, H. Lode, Zsófia Mészner, Roman Prymula, Galia Rahav, Anna Skoczyńska, Ivan Solovič, Esra Uzaslan	5
19	Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel 2012 ·Clinical Microbiology and Infection ·Ronen Ben‐Ami, Galia Rahav, Hila Elinav, Imad Kassis, Itamar Shalit, Tamar Gottesman, Orli Megged, Miriam Weinberger, (unknown), Pnina Shitrit, Regina Weber, Alona Paz, Dan Miron, I. Oren, Jihad Bishara, Colin Block, Nathan Keller, Dimitrios P. Kontoyiannis, Michael Giladi	19
20	Changing parents’ opinions regarding antibiotic use in primary care 2010 ·European Journal of Pediatrics ·(unknown), ‪Yasmin Maor‬‏, Meir Raz, Ethan Rubinstein, (unknown), (unknown), (unknown), Galia Rahav, Gili Regev‐Yochay	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact